Dianthus Therapeutics (DNTH) Net Cash Flow (2017 - 2025)

Dianthus Therapeutics has reported Net Cash Flow for 9 years, with the latest figure at $42.7 million in Q3 2025.

• For the quarter ending Q3 2025, Net Cash Flow rose 115.23% year-over-year to $42.7 million; the trailing twelve-month figure through Dec 2025 stood at $33.1 million (up 130.29% YoY), and the FY2024 full-year result was -$109.4 million, down 193.5% from the prior year.
• Net Cash Flow for Q3 2025 stood at $42.7 million, up from $3.1 million in the prior quarter.
• The five-year high for Net Cash Flow was $197.4 million in Q1 2024, with the low at -$280.3 million in Q3 2024.
• Average Net Cash Flow over 5 years is $6.4 million, with a median of -$8.9 million recorded in 2021.
• Peak annual rise in Net Cash Flow reached 4136.37% in 2022, while the deepest fall reached 575.67% in 2022.
• Tracing DNTH's Net Cash Flow over 5 years: stood at -$25.9 million in 2021, then rose by 16.89% to -$21.5 million in 2022, then dropped by 15.99% to -$25.0 million in 2023, then soared by 56.41% to -$10.9 million in 2024, then soared by 492.38% to $42.7 million in 2025.
• The last three Net Cash Flow figures came in at $42.7 million (Q3 2025), $3.1 million (Q2 2025), and -$12.7 million (Q1 2025), per Business Quant data.

Peer Comparison